Cargando…
A 10-year retrospective study of lung cancer in Uganda
BACKGROUND: Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI). METHODS: We retrospectively reviewed medical records of all patients with a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867773/ https://www.ncbi.nlm.nih.gov/pubmed/35197014 http://dx.doi.org/10.1186/s12885-022-09300-1 |
_version_ | 1784656121962692608 |
---|---|
author | Bogere, Naghib Bongomin, Felix Katende, Andrew Omaido, Blair Andrew Namukwaya, Elizabeth Mayanja-Kizza, Harriet Walusansa, Victoria |
author_facet | Bogere, Naghib Bongomin, Felix Katende, Andrew Omaido, Blair Andrew Namukwaya, Elizabeth Mayanja-Kizza, Harriet Walusansa, Victoria |
author_sort | Bogere, Naghib |
collection | PubMed |
description | BACKGROUND: Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI). METHODS: We retrospectively reviewed medical records of all patients with a histological diagnosis of lung cancer registered at UCI between January 2008 and August 2018. Data on demographic, clinical, and treatment characteristics, and vital status were abstracted and analyzed. Patients with undocumented vital status on the medical records were contacted through phone calls. We determined survival as time from histological diagnosis to death. The Kaplan-Meier survival analysis was performed to estimate the median survival time and the 5-year overall survival rate. RESULTS: Of the 207 patients enrolled, 56.5% (n = 117) were female, median age was 60 years (range: 20–94), 78.7% (n = 163) were never-smokers and 18 (8.7%) were living with HIV. Presumptive anti-tuberculosis treatment was given to 23.2% (n = 48). Majority had non-small cell lung cancer (96.6%, n = 200) with 74.5% (n = 149) adenocarcinoma and 19% (n = 38) squamous cell carcinoma. All had advanced (stage III or IV) disease with 96.1% (n = 199) in stage IV. Chemotherapy (44.9%, n = 93) and biological therapy (34.8%, n = 72) were the commonest treatments used. Overall survival at 6 months, 1-, 2- and 5-years was 41.7, 29.7, 11.8, and 1.7%, respectively. The median survival time of 4.4 months was not statistically significantly different between participants with NSCLC or SCLC (4.5 versus 3.9 months, p = .335). CONCLUSION: In Uganda, adenocarcinoma is the predominant histologic subtype of lung cancer and patients are predominantly females, and non-smokers. Patients present late with advanced disease and poor overall survival. Public awareness should be heightened to facilitate early detection and improve outcomes. |
format | Online Article Text |
id | pubmed-8867773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88677732022-02-25 A 10-year retrospective study of lung cancer in Uganda Bogere, Naghib Bongomin, Felix Katende, Andrew Omaido, Blair Andrew Namukwaya, Elizabeth Mayanja-Kizza, Harriet Walusansa, Victoria BMC Cancer Research BACKGROUND: Lung cancer is a leading cause of cancer-related deaths in Uganda. In this study, we aimed to describe the baseline characteristics and survival of patients with lung cancer at the Uganda Cancer Institute (UCI). METHODS: We retrospectively reviewed medical records of all patients with a histological diagnosis of lung cancer registered at UCI between January 2008 and August 2018. Data on demographic, clinical, and treatment characteristics, and vital status were abstracted and analyzed. Patients with undocumented vital status on the medical records were contacted through phone calls. We determined survival as time from histological diagnosis to death. The Kaplan-Meier survival analysis was performed to estimate the median survival time and the 5-year overall survival rate. RESULTS: Of the 207 patients enrolled, 56.5% (n = 117) were female, median age was 60 years (range: 20–94), 78.7% (n = 163) were never-smokers and 18 (8.7%) were living with HIV. Presumptive anti-tuberculosis treatment was given to 23.2% (n = 48). Majority had non-small cell lung cancer (96.6%, n = 200) with 74.5% (n = 149) adenocarcinoma and 19% (n = 38) squamous cell carcinoma. All had advanced (stage III or IV) disease with 96.1% (n = 199) in stage IV. Chemotherapy (44.9%, n = 93) and biological therapy (34.8%, n = 72) were the commonest treatments used. Overall survival at 6 months, 1-, 2- and 5-years was 41.7, 29.7, 11.8, and 1.7%, respectively. The median survival time of 4.4 months was not statistically significantly different between participants with NSCLC or SCLC (4.5 versus 3.9 months, p = .335). CONCLUSION: In Uganda, adenocarcinoma is the predominant histologic subtype of lung cancer and patients are predominantly females, and non-smokers. Patients present late with advanced disease and poor overall survival. Public awareness should be heightened to facilitate early detection and improve outcomes. BioMed Central 2022-02-23 /pmc/articles/PMC8867773/ /pubmed/35197014 http://dx.doi.org/10.1186/s12885-022-09300-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bogere, Naghib Bongomin, Felix Katende, Andrew Omaido, Blair Andrew Namukwaya, Elizabeth Mayanja-Kizza, Harriet Walusansa, Victoria A 10-year retrospective study of lung cancer in Uganda |
title | A 10-year retrospective study of lung cancer in Uganda |
title_full | A 10-year retrospective study of lung cancer in Uganda |
title_fullStr | A 10-year retrospective study of lung cancer in Uganda |
title_full_unstemmed | A 10-year retrospective study of lung cancer in Uganda |
title_short | A 10-year retrospective study of lung cancer in Uganda |
title_sort | 10-year retrospective study of lung cancer in uganda |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867773/ https://www.ncbi.nlm.nih.gov/pubmed/35197014 http://dx.doi.org/10.1186/s12885-022-09300-1 |
work_keys_str_mv | AT bogerenaghib a10yearretrospectivestudyoflungcancerinuganda AT bongominfelix a10yearretrospectivestudyoflungcancerinuganda AT katendeandrew a10yearretrospectivestudyoflungcancerinuganda AT omaidoblairandrew a10yearretrospectivestudyoflungcancerinuganda AT namukwayaelizabeth a10yearretrospectivestudyoflungcancerinuganda AT mayanjakizzaharriet a10yearretrospectivestudyoflungcancerinuganda AT walusansavictoria a10yearretrospectivestudyoflungcancerinuganda AT bogerenaghib 10yearretrospectivestudyoflungcancerinuganda AT bongominfelix 10yearretrospectivestudyoflungcancerinuganda AT katendeandrew 10yearretrospectivestudyoflungcancerinuganda AT omaidoblairandrew 10yearretrospectivestudyoflungcancerinuganda AT namukwayaelizabeth 10yearretrospectivestudyoflungcancerinuganda AT mayanjakizzaharriet 10yearretrospectivestudyoflungcancerinuganda AT walusansavictoria 10yearretrospectivestudyoflungcancerinuganda |